Subscribe
Subscribe for the Newsletter
Mobile Navigation
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Experience
Market Research
Directory
Close
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
ADC
Sort By
Newest First
Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.
Explore
About Us
Nice Insight
That's Nice
Reach Our Team
Contact Us
Advertise
LinkedIn
My Account
Login
Sign up
Subscribe for the newsletter
© 2026 PHARMA'S ALMANAC. All rights reserved.
Privacy Policy
Terms And Conditions
(54)
1 / 3
U.S. CDMO Capacity
More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand
Pharma's Almanac
PAO-06-26-PA-18
Jun 22, 2026
Roundtable
How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?
Pharma's Almanac
PAO-05-26-RT-02
May 27, 2026
ADCs
Re-Engineering ADCs for Autoimmune and Inflammatory Disease
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-20
May 21, 2026
Conjugation
Why ADC Conjugation Strategy Is Now a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-18
May 20, 2026
ADC Platform
From mAbs to ADCs: Rethinking the Platform Manufacturing Model
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-11
May 11, 2026
ADC Linkers
Linker Chemistry as the Hidden Determinant of ADC Success
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-10
May 8, 2026
ADC Engineering
Engineering Antibodies for Precision Payload Delivery
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-04
May 4, 2026
Conjugate Payloads
Beyond Cytotoxins: Expanding the Payload Landscape for Antibody-Based Conjugates
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-03
May 1, 2026
ADCs
Accelerating ADC Analytical Method Development Through Platform Innovation
Jaeook Kim, Ph.D.
Samsung Biologics
PAO-03-26-CL-06
Mar 23, 2026
ADCs
Improved Efficacy and Safety Driving Resurging Interest in ADCs
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-09-25-NI-05
Sep 22, 2025
Ovarian Cancer
Ovarian Cancer at an Inflection Point: Quantifying the Burden, Closing Gaps, and Accelerating Next-Generation Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-25-NI-03
Sep 10, 2025
Biotechs
Next-Gen Biopharma: The Startups Leading the Charge
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-25-NI-12
Aug 26, 2025
Biomanufacturing
Organoids, ADCs, and More on the Horizon at Samsung Biologics
Kevin Sharp
Samsung Biologics
PAO-08-25-BIO-02
Aug 22, 2025
Continuous
Novel Integration of Process Analytical Technologies for Continuous Biomanufacturing
Edita Botonjic-Sehic, Ph.D.
Recipharm Advanced Bio
PAO-07-25-CL-05
Aug 6, 2025
Next-Gen Biologics
What do you see as the next big modality in biologics, and what factors are driving innovation in this space?
Pharma's Almanac
PAO-04-25-RT-01
May 1, 2025
Radioconjugates
Rising Interest in Radioconjugate Therapies
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-02-25-NI-05
Feb 25, 2025
FDA
Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65 Powered by AxcynDOT™ Technology
Axcynsis Therapeutics
PR-01-25-NI-19
Jan 16, 2025
Announcement
Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration with BeiGene
Nona Biosciences
PR-01-25-NI-02
Jan 3, 2025
CDMO
The Improvements of the Production and Stability of a mAb-Chelator Conjugate by Modified Transchelation Conditions
Hyung-il Lee, Ph.D.
GBI Biomanufacturing
PAO-11-24-CL-09
Dec 20, 2024
ADC
Chime Biologics and Waterstone Jointly Develop and Manufacture Antibody-Drug Conjugate (ADC)
Chime Biologics
PR-10-24-NI-91
Nov 12, 2024
1 / 3